Background

The success of cancer immunotherapy depends on the precision of inducing the immune system to identify and destroy only cancer cells without attacking normal cells. While immune checkpoint inhibitors and CAR-T cell therapies have achieved significant results in solid and hematologic cancers, on-target, off-tumor toxicity remains a challenge. This is because most tumor-associated antigens (TAAs) are expressed in trace amounts in normal tissues, potentially causing autoimmune responses or fatal organ damage. Patient-specific neoantigens offer excellent tumor specificity, but face high commercialization barriers in terms of production cost and time because individual therapeutic agents must be manufactured following genetic mutation analysis for each patient. Consequently, research aimed at identifying broadly shared targets that are rarely expressed in normal tissues but commonly appear across multiple cancer types is gaining renewed momentum.

In this context, cancer-testis antigens (CTAs) are gaining attention. CTAs are a group of proteins that are expressed exclusively in the seminiferous tubules of the testes, an immune-privileged site in healthy adult humans, and in the trophoblast cells of the placenta. Testicular cells do not express major histocompatibility complex (MHC) class I molecules, thereby avoiding direct attack by cytotoxic T lymphocytes (CD8+ T cells). Thanks to the blood-testis barrier, they are isolated from immune responses. In contrast, various epithelial malignancies exhibit abnormal reactivation of these genes due to epigenetic abnormalities. It is close to the biological ideal of being able to target only cancer cells while fundamentally avoiding normal cell toxicity.

Key Findings

Recent molecular biology data have detailed the genetic and epigenetic regulatory mechanisms that trigger the abnormal expression of CTAs. In normally differentiated cells, CTA gene promoter regions remain silenced through high-density DNA methylation and histone modification. In the tumor microenvironment, widespread demethylation occurs due to DNA methyltransferase (DNMT) inhibition or abnormal activation of transcription factors, causing closed chromatin structures to open and leading to a surge in the expression of key CTAs such as MAGE, NY-ESO-1, PRAME, and SSX. Notably, the CT-X gene cluster located on the X chromosome exhibited simultaneous expression in progressive cancer cells.

CTAs do not merely serve as immune markers; they act as functional mediators that amplify the malignancy and metastatic potential of cancer cells. These proteins help bypass cell cycle checkpoints, promote p53 ubiquitination to block tumor suppressor signals, and stimulate the epithelial-mesenchymal transition (EMT) pathway to enhance cancer cell invasiveness.

An even more critical characteristic is the potent immunogenicity of CTAs. Because they have not undergone, or have evaded, the negative selection process in the human thymus, the human immune system recognizes CTA peptides presented on the surface of cancer cells as foreign antigens equivalent to external invaders. It has been confirmed that CTA-derived peptides bind with high affinity to major MHC molecules, such as HLA-A*0201, inducing robust tumor-reactive CD8+ cytotoxic T cell proliferation and forming a memory T cell pool that mediates long-term anti-tumor responses.

Significance and Outlook

The elucidation of CTA biology expands the development pathways for various modalities, including cancer vaccines, TCR-T cell therapies, and antibody-drug conjugates (ADCs). While early peptide vaccine studies failed to sufficiently prove clinical efficacy due to single-target use and immature adjuvants, the latest therapeutic platforms are increasing response rates by combining multivalent mRNA vaccines with high-affinity T-cell receptor (TCR) engineering technology. TCR-T cell therapies targeting NY-ESO-1 and PRAME have already entered the commercialization stage, reporting significant objective response rates (ORR) in synovial sarcoma and melanoma clinical trials.

Clear limitations also remain. Antigen expression heterogeneity within solid tumors is a major cause of immune escape. If not all cells within a tumor express CTAs uniformly, antigen-negative variant cells may survive selectively, leading to recurrence. To overcome this, epigenetic priming strategies—using low-dose demethylating agents (e.g., 5-azacytidine) to artificially homogenize CTA expression throughout the tumor—are being actively validated. Research into targeting atypical CTAs exposed on the cell membrane, rather than just intracellular proteins, via ADCs or bispecific antibodies, is also identified as an essential task.